Minwoo Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Minwoo Lee has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Kyomin Jung
Seoul National University
4 shared publications Dongryeol Lee
Dept. of ECE Seoul National University
2 shared publications- Heeyoung Kwak
Seoul National University
2 shared publications - Hwanhee Lee
Chung-Ang University Seoul Korea
2 shared publications - Joonsuk Park
University of Richmond
2 shared publications - Sang-Woo Lee
NAVER AI Lab
2 shared publications
Latest Publications
- Open Access
Asking Clarification Questions to Handle Ambiguity in Open-Domain QA
Ambiguous questions persist in open-domain question answering, because formulating a precise question with a unique answer is often challenging. Previously, Min et al. (2020) have tackled this issue by generating disambiguated questions for all possible interpretations of the ambiguous question. This can be effective, but not ideal for providing an answer to the user. Instead, we propose to ask a clarification question, where the user's response will help identify the interpretation that best aligns with the user's intention. We first present CAMBIGNQ, a dataset consisting of 5,654 ambiguous questions, each with relevant passages, possible answers, and a clarification question. The clarification questions were efficiently created by generating them using InstructGPT and manually revising them as necessary. We then define a pipeline of tasks and design appropriate evaluation metrics. Lastly, we achieve 61.3 F1 on ambiguity detection and 40.5 F1 on clarification-based QA, providing strong baselines for future work.
Open AccessAsking Clarification Questions to Handle Ambiguity in Open-Domain QA
Ambiguous questions persist in open-domain question answering, because formulating a precise question with a unique answer is often challenging. Previously, Min et al. (2020) have tackled this issue by generating disambiguated questions for all possible interpretations of the ambiguous question. This can be effective, but not ideal for providing an answer to the user. Instead, we propose to ask a clarification question, where the user's response will help identify the interpretation that best aligns with the user's intention. We first present CAMBIGNQ, a dataset consisting of 5,654 ambiguous questions, each with relevant passages, possible answers, and a clarification question. The clarification questions were efficiently created by generating them using InstructGPT and manually revising them as necessary. We then define a pipeline of tasks and design appropriate evaluation metrics. Lastly, we achieve 61.3 F1 on ambiguity detection and 40.5 F1 on clarification-based QA, providing strong baselines for future work.
- Top Cited PapersOpen Access
- 1 January 2023
- Published by Association for Computational Linguistics (ACL)
- p. 11526-11544
Asking Clarification Questions to Handle Ambiguity in Open-Domain QA
Dongryeol Lee, Segwang Kim, Minwoo Lee, Hwanhee Lee, Joonsuk Park, Sang-Woo Lee, Kyomin Jung. Findings of the Association for Computational Linguistics: EMNLP 2023. 2023.
- 1 January 2023
- Published by Association for Computational Linguistics (ACL)
- p. 11526-11544
Top Cited PapersOpen AccessAsking Clarification Questions to Handle Ambiguity in Open-Domain QA
Dongryeol Lee, Segwang Kim, Minwoo Lee, Hwanhee Lee, Joonsuk Park, Sang-Woo Lee, Kyomin Jung. Findings of the Association for Computational Linguistics: EMNLP 2023. 2023.
- 6 May 2020
- Published by Springer Nature
- Vol. 12085, 633-644
Drug-Disease Graph: Predicting Adverse Drug Reaction Signals via Graph Neural Network with Clinical Data
Adverse Drug Reaction (ADR) is a significant public health concern world-wide. Numerous graph-based methods have been applied to biomedical graphs for predicting ADRs in pre-marketing phases. ADR detection in post-market surveillance is no less important than pre-marketing assessment, and ADR detection with large-scale clinical data have attracted much attention in recent years. However, there are not many studies considering graph structures from clinical data for detecting an ADR signal, which is a pair of a prescription and a diagnosis that might be a potential ADR. In this study, we develop a novel graph-based framework for ADR signal detection using healthcare claims data. We construct a Drug-disease graph with nodes representing the medical codes. The edges are given as the relationships between two codes, computed using the data. We apply Graph Neural Network to predict ADR signals, using labels from the Side Effect Resource database. The model shows improved AUROC and AUPRC performance of 0.795 and 0.775, compared to other algorithms, showing that it successfully learns node representations expressive of those relationships. Furthermore, our model predicts ADR pairs that do not exist in the established ADR database, showing its capability to supplement the ADR database.
- 6 May 2020
- Published by Springer Nature
- Vol. 12085, 633-644
Drug-Disease Graph: Predicting Adverse Drug Reaction Signals via Graph Neural Network with Clinical Data
Adverse Drug Reaction (ADR) is a significant public health concern world-wide. Numerous graph-based methods have been applied to biomedical graphs for predicting ADRs in pre-marketing phases. ADR detection in post-market surveillance is no less important than pre-marketing assessment, and ADR detection with large-scale clinical data have attracted much attention in recent years. However, there are not many studies considering graph structures from clinical data for detecting an ADR signal, which is a pair of a prescription and a diagnosis that might be a potential ADR. In this study, we develop a novel graph-based framework for ADR signal detection using healthcare claims data. We construct a Drug-disease graph with nodes representing the medical codes. The edges are given as the relationships between two codes, computed using the data. We apply Graph Neural Network to predict ADR signals, using labels from the Side Effect Resource database. The model shows improved AUROC and AUPRC performance of 0.795 and 0.775, compared to other algorithms, showing that it successfully learns node representations expressive of those relationships. Furthermore, our model predicts ADR pairs that do not exist in the established ADR database, showing its capability to supplement the ADR database.
- Open Access
Drug-disease Graph: Predicting Adverse Drug Reaction Signals via Graph Neural Network with Clinical Data
Adverse Drug Reaction (ADR) is a significant public health concern world-wide. Numerous graph-based methods have been applied to biomedical graphs for predicting ADRs in pre-marketing phases. ADR detection in post-market surveillance is no less important than pre-marketing assessment, and ADR detection with large-scale clinical data have attracted much attention in recent years. However, there are not many studies considering graph structures from clinical data for detecting an ADR signal, which is a pair of a prescription and a diagnosis that might be a potential ADR. In this study, we develop a novel graph-based framework for ADR signal detection using healthcare claims data. We construct a Drug-disease graph with nodes representing the medical codes. The edges are given as the relationships between two codes, computed using the data. We apply Graph Neural Network to predict ADR signals, using labels from the Side Effect Resource database. The model shows improved AUROC and AUPRC performance of 0.795 and 0.775, compared to other algorithms, showing that it successfully learns node representations expressive of those relationships. Furthermore, our model predicts ADR pairs that do not exist in the established ADR database, showing its capability to supplement the ADR database.
Open AccessDrug-disease Graph: Predicting Adverse Drug Reaction Signals via Graph Neural Network with Clinical Data
Adverse Drug Reaction (ADR) is a significant public health concern world-wide. Numerous graph-based methods have been applied to biomedical graphs for predicting ADRs in pre-marketing phases. ADR detection in post-market surveillance is no less important than pre-marketing assessment, and ADR detection with large-scale clinical data have attracted much attention in recent years. However, there are not many studies considering graph structures from clinical data for detecting an ADR signal, which is a pair of a prescription and a diagnosis that might be a potential ADR. In this study, we develop a novel graph-based framework for ADR signal detection using healthcare claims data. We construct a Drug-disease graph with nodes representing the medical codes. The edges are given as the relationships between two codes, computed using the data. We apply Graph Neural Network to predict ADR signals, using labels from the Side Effect Resource database. The model shows improved AUROC and AUPRC performance of 0.795 and 0.775, compared to other algorithms, showing that it successfully learns node representations expressive of those relationships. Furthermore, our model predicts ADR pairs that do not exist in the established ADR database, showing its capability to supplement the ADR database.